alexa Good and Prolonged Response to Low Dose Capecitabine as
ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Good and Prolonged Response to Low Dose Capecitabine as Second Line Therapy in a Patient with Advanced Hepatocellular Carcinoma

Caterina Soldà1*, Giuseppe Lombardi2, Camillo Aliberti3, Silvano Fasolato4, Paolo Angeli4, Davide Pastorelli1

1Rare Tumors Unit, Veneto Institute of Oncology IOV IRCCS, Via Gattamelata, Padova, Italy

2Department of Experimental and Clinical Oncology, Medical Oncology Unit, Veneto Institute of Oncology -IRCCS, Via Padova, Italy

3Interventional Radiology Unit, Department of Radiology, Veneto Institute of Oncology IOV IRCCS, Via Padova, Italy

4Unit of Medical Emergencies in Liver Transplantation, Department of Surgery University of Padova, Italy

*Corresponding Author:
Caterina Soldà
Rare Tumors Unit, Veneto Institute of Oncology– IRCCS. Italy
Tel: +390498215917
Email: [email protected]

Received Date: August 22, 2015 Accepted Date: December 18, 2015 Published Date: December 23, 2015

Citation: Soldà C, Lombardi G, Aliberti C, Fasolato S,Angeli P, Pastorelli D (2015) Good and Prolonged Response to Low Dose Capecitabine as Second Line Therapy in a Patient with Advanced Hepatocellular Carcinoma. Chemo Open Access 5:181. doi: 10.4172/2167-7700.1000181

Copyright: © 2015 Soldà, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Sorafenib is the only validated pharmacological treatment option for patients with advanced hepatocellular carcinoma (HCC) in the context of Child-Pugh class A liver function. Effective and safe systemic treatments for advanced disease with severe underlying cirrhosis (Child-Pugh class B and C) are not yet available. A few reports have described capecitabine as an option after failure of sorafenib or for patients who were not eligible for clinical trials. Here, we present a case of good response to low dose capecitabine in a patient with advanced HCC.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version